Innovative Medical Breakthroughs
Unleashing the Power of Synthetic Cannabinoids to Transform Rare Disease Treatment.
EPM Therapeutics: Revolutionizing medical treatments with cutting-edge synthetic cannabinoid science, transforming lives with innovative therapies for unmet medical needs.
Unleashing the Power of Synthetic Cannabinoids to Transform Rare Disease Treatment.
At EPM Therapeutics, we're on a mission to revolutionize medicine by developing cutting-edge synthetic cannabinoid acid derivatives to tackle unmet medical needs.
Meet EPM301, our groundbreaking stable CBDA analogue designed to combat hyperphagia, the most challenging symptom of Prader-Willi Syndrome (PWS).
With a focus on expanding our patent portfolio and advancing towards Phase 1/2a clinical trials, we're dedicated to making a difference in the lives of those with rare diseases.
Backed by a stellar scientific team and strategic partnerships, EPM Therapeutics is at the forefront of addressing the significant unmet medical needs in the PWS market.
Dr. Raphael Mechoulam, the Iconic ‘Father of Cannabis,’
Professor Raphael Mechoulam
Father of Cannabis Research
EPM Therapeutics Team
Medical Mavericks
01
Revolutionary CBDA analogue targeting hyperphagia in PWS patients.
02
Diversifying our portfolio to drive future medical advancements.
03
Advancing towards Phase 1/2a trials for EPM301 efficacy testing.
04
Harnessing top-tier talent for cutting-edge medical research.
Dr. Raphael Mechoulam
Clinical Trials Specialist
Joseph Tam, Ph.D.
Lead Researcher
Explore the Future of Medicine with EPM Therapeutics
Peter Welburn, Ph.D.
Chief Medical Officer
Phil Rose, R.Ph.
President & COO
Jaime Rodriguez
Chief Strategy Officer
97%
Turning Dreams into Reality
120+
Fueling Innovation Beyond Boundaries
$1B+
Funding Tomorrow's Breakthroughs
10+
Collaborating for a Healthier World
Explore Now
Step into the world of EPM Therapeutics through captivating images showcasing our journey towards groundbreaking medical advancements.
Embark on a mind-bending journey with EPM Therapeutics, the trailblazers in synthetic cannabinoid acid derivatives. Witness the magic of EPM301 as it battles Prader-Willi Syndrome with unparalleled ferocity and finesse.
Be a part of the future in medical innovation.
Cannabis Visionary
Raphael Mechoulam
Witness the Power of Innovation and Science Combined.
EPM Therapeutics Team
Medical Mavericks
EPM301 is a stable CBDA analogue targeting Prader-Willi Syndrome.
Join us in revolutionizing healthcare by exploring partnership opportunities.
Experience the future of medicine with our cutting-edge solutions.
Our headquarters are in the heart of medical innovation, Silicon Valley.
We stand out through our commitment to excellence and groundbreaking research.
Reach out to us via email, phone, or visit our headquarters for a personal meeting.
